A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the long-term efficacy of nebivolol monotherapy in patients with stage 1 or stage 2 hypertension after the withdrawal of active medication.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories
• Treatments: Nebivolol

Criteria

Inclusion Criteria:

• male and female outpatients 18 to 79 years of age

• Females must be post-menopausal, or not pregnant and using an approved contraceptive regimen

• meet criteria for stage I or II hypertension

• currently not treated, or being treated with no more than two anti-hypertensive medications

Exclusion Criteria:

• type 1 or type 2 diabetes

• secondary hypertension

• evidence of other concurrent disease or conditions that might interfere with the conduct of the study

• treatment with any investigational study drug within 30 days of Screening (Visit 1)

• have a history of hypersensitivity to nebivolol or other β-blockers